India, Sept. 3 -- Attovia Therapeutics Inc. (ATTO), a clinical stage biopharmaceutical company, on Wednesday reported a wider net loss in financial results for the second quarter, owing to increased clinical, preclinical, and manufacturing costs.
The company discovers new drug candidates using its proprietary ATTOBODY biparatopic biologics platform. These include ATTO-1310, under development for chronic pruritic diseases; ATTO-2306, a bispecific antibody for atopic dermatitis; and ATTO-1091, a trispecific antibody for inflammatory bowel diseases. Q2 Financial Readout:
Net loss expanded to $20.69 million or $4.88 per share in the second quarter, compared to $14.44 million or $3.71 per share in the same period of the previous year. This was...